- Home
- SMX vs APM Comparison
SMX vs APM Comparison
Compare SMX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMX
- APM
- Stock Information
- Founded
- SMX N/A
- APM 2010
- Country
- SMX Ireland
- APM United Kingdom
- Employees
- SMX N/A
- APM N/A
- Industry
- SMX Industrial Machinery/Components
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- SMX Technology
- APM Health Care
- Exchange
- SMX Nasdaq
- APM Nasdaq
- Market Cap
- SMX 6.7M
- APM 6.9M
- IPO Year
- SMX N/A
- APM 2018
- Fundamental
- Price
- SMX $4.28
- APM $2.64
- Analyst Decision
- SMX
- APM
- Analyst Count
- SMX 0
- APM 0
- Target Price
- SMX N/A
- APM N/A
- AVG Volume (30 Days)
- SMX 1.3M
- APM 20.0M
- Earning Date
- SMX 01-01-0001
- APM 04-30-2025
- Dividend Yield
- SMX N/A
- APM N/A
- EPS Growth
- SMX N/A
- APM N/A
- EPS
- SMX N/A
- APM N/A
- Revenue
- SMX N/A
- APM N/A
- Revenue This Year
- SMX N/A
- APM N/A
- Revenue Next Year
- SMX N/A
- APM N/A
- P/E Ratio
- SMX N/A
- APM N/A
- Revenue Growth
- SMX N/A
- APM N/A
- 52 Week Low
- SMX $3.85
- APM $0.46
- 52 Week High
- SMX $5,925.93
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- SMX 30.72
- APM 59.96
- Support Level
- SMX $4.75
- APM $1.26
- Resistance Level
- SMX $5.74
- APM $4.47
- Average True Range (ATR)
- SMX 0.99
- APM 0.26
- MACD
- SMX 0.55
- APM 0.17
- Stochastic Oscillator
- SMX 7.67
- APM 43.87
About SMX SMX (Security Matters) Public Limited Company
SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.